Does the GLP-1 receptor agonist (Victoza) improve the metabolic response to physical training in patients with type 2 diabetes?

Trial Profile

Does the GLP-1 receptor agonist (Victoza) improve the metabolic response to physical training in patients with type 2 diabetes?

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Sep 2017 Results (n=19) assessing effect of liraglutide treatment combined with exercise training on the bone formation markers osteocalcin and procollagen type-1 aminoterminal propeptide, the bone resorption marker C-terminal telopeptide of type 1 collagen, whole-body BMD and wholebody bone mineral content presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
    • 13 Jun 2017 Results of bone turnover during exercise training (n=19) presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top